| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
In A549 cells, thymol (20 μM, 24-48 hours) affects the expression of IL4I1 (24 hours) and the aromatic channel receptor (AHR) signaling pathway (48 hours) [2]. Thymol (5 μM, 48 hours) A549 Thymol (0-600 μM, 48 hours) modulation suppresses the epithelial-to-mesenchymal transition, motor activity, and cell proliferation in several binary types (Cal27, SCC4, SCC9, HeLa, H460, MDA-231, and PC3 cells) [2]. In A, thymol (200 μg/mL) causes conidia acetone that is reliant on caspase. flavus [4].
|
|---|---|
| ln Vivo |
In an orthotopic mouse lung adenocarcinoma (LUAD) model, thymol (75 mg/kg, i.p.) alone and in combination with anti-PD-1 antibody (10 mg/kg, i.p.) both decrease LUAD progression and make animals more susceptible to anti-PD-1 antagonist therapy [2]. In Cal27-derived xenograft mice, thymol (4.3 mM in 50 μL of sterile saline, intratumoral injection, daily) demonstrated anticancer efficacy.
|
| Cell Assay |
Western blot analysis [2]
Cell Types: A549 cells Tested Concentrations: 20 μM incubation. Incubation Duration: 48 h Experimental Results: Inhibition of IL4I1 protein levels and AHR nuclear translocation. diminished overall AHR level. |
| Animal Protocol |
Animal/Disease Models: Orthotopic mouse LUAD model [2]
Doses: Thymol 75 mg/kg, anti-PD-1 antibody 10 mg/kg Route of Administration: anti-PD-1 antibody: intraperitoneal (ip) injection, once every 1 week. Day 5 after tumor injection. Thymol: intraperitoneally (ip) (ip), every 2 days starting on day 5 after tumor injection. Experimental Results: Inhibited the progression of LUAD and improved the survival rate of mice. Reduce IL4I1 levels in tumors. Improve the efficacy of anti-PD-1 antibodies. |
| References |
[1]. Marchese A, et al. Antibacterial and antifungal activities of thymol: A brief review of the literature. Food Chem. 2016 Nov 1;210:402-14.
[2]. Li T, et al. Thymol targeting interleukin 4 induced 1 expression reshapes the immune microenvironment to sensitize the immunotherapy in lung adenocarcinoma. MedComm (2020). 2023 Aug 30;4(5):e355. [3]. De La Chapa JJ, et al. Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis. J Oral Pathol Med. 2018 Aug;47(7):674-682. [4]. Hu LB, et al. Thymol Induces Conidial Apoptosis in Aspergillus flavus via Stimulating K+ Eruption. J Agric Food Chem. 2018 Aug 15;66(32):8530-8536. |
| Molecular Formula |
C10H14O
|
|---|---|
| Molecular Weight |
150.22
|
| Exact Mass |
150.1045
|
| CAS # |
89-83-8
|
| Related CAS # |
Thymol-d13;1219798-93-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O([H])C1C([H])=C(C([H])([H])[H])C([H])=C([H])C=1C([H])(C([H])([H])[H])C([H])([H])[H]
|
| Synonyms |
NSC-11215; NSC 11215; Thymol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~832.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (13.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (13.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (13.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6569 mL | 33.2845 mL | 66.5690 mL | |
| 5 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL | |
| 10 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
